Search research articles
Contact Us
Filters
Showing results (141-150 of 192) with videos related to
Page
of 20
Sort By:
Pathogens & Immunity
|
November 21, 2025
Three-Month cART Initiated During Primary HIV Does Not Correct the Structural, Immune, and Microbial Abnormalities within the Gastrointestinal Tract
Camilla Tincati, Valeria Bono, Silvia Nozza, et al.
International Journal of Antimicrobial Agents
|
January 12, 2024
Characterization and outcomes of difficult-to-treat patients starting modern first-line ART regimens: Data from the ICONA cohort
Roberta Gagliardini, Alessandro Tavelli, Stefano Rusconi, et al.
Current HIV Research
|
July 16, 2009
Clinical validation and applicability of different tipranavir/ritonavir genotypic scores in HIV-1 protease inhibitor-experienced patients
Annalisa Saracino, Laura Monno, Alessandra Tartaglia, et al.
Medicine
|
November 3, 2021
Has COVID-19 changed the approach to HIV diagnosis?: A multicentric Italian experience
Maria Mazzitelli, Arturo Ciccullo, Gianmaria Baldin, et al.
Journal of Global Antimicrobial Resistance
|
April 12, 2025
Role of low-frequency integrase strand transfer inhibitor resistance mutations on virological outcomes in antiretroviral therapy-naïve individuals initiating second-generation integrase inhibitors
Daniele Armenia, Greta Marchegiani, Daniele Spalletta, et al.
Plos One
|
September 28, 2019
A prospective randomized trial on abacavir/lamivudine plus darunavir/ritonavir or raltegravir in HIV-positive drug-naïve patients with CD4<200 cells/uL (the PRADAR study)
Cristina Mussini, Enrica Roncaglia, Vanni Borghi, et al.
The Journal of Antimicrobial Chemotherapy
|
May 15, 2026
'Leaving no stones unturned': up to 10 years results on the effectiveness, tolerability and metabolic safety of dolutegravir+lamivudine (DTG+3TC) as a switch regimen in the ODOACRE cohort
Arturo Ciccullo, Gianmaria Baldin, Adriana Cervo, et al.
Expert Review of Anti-Infective Therapy
|
October 15, 2020
Enhancing care for people living with HIV: current and future monitoring approaches
Franco Maggiolo, Alessandra Bandera, Stefano Bonora, et al.
The Lancet. HIV
|
February 28, 2024
Switching to dolutegravir plus rilpivirine versus maintaining current antiretroviral therapy regimen in virologically suppressed people with HIV-1 and the Lys103Asn (K103N) mutation: 48-week results from a randomised, open-label pilot clinical trial
Graeme Moyle, Lambert Assoumou, Nathalie de Castro, et al.
Immunity, Inflammation and Disease
|
February 25, 2023
Reduced probability of improving viro-immunological state in subjects with vertical transmission of HIV reaching adult age: A multicenter retrospective cohort study
Francesca Pennati, Stefano Calza, Antonio Di Biagio, et al.
Page
of 20
Search research articles
Search
Showing results (141-150 of 192) with videos related to
Sort By:
Page
of 20
Pathogens & Immunity
|
November 21, 2025
Three-Month cART Initiated During Primary HIV Does Not Correct the Structural, Immune, and Microbial Abnormalities within the Gastrointestinal Tract
Camilla Tincati, Valeria Bono, Silvia Nozza, et al.
International Journal of Antimicrobial Agents
|
January 12, 2024
Characterization and outcomes of difficult-to-treat patients starting modern first-line ART regimens: Data from the ICONA cohort
Roberta Gagliardini, Alessandro Tavelli, Stefano Rusconi, et al.
Current HIV Research
|
July 16, 2009
Clinical validation and applicability of different tipranavir/ritonavir genotypic scores in HIV-1 protease inhibitor-experienced patients
Annalisa Saracino, Laura Monno, Alessandra Tartaglia, et al.
Medicine
|
November 3, 2021
Has COVID-19 changed the approach to HIV diagnosis?: A multicentric Italian experience
Maria Mazzitelli, Arturo Ciccullo, Gianmaria Baldin, et al.
Journal of Global Antimicrobial Resistance
|
April 12, 2025
Role of low-frequency integrase strand transfer inhibitor resistance mutations on virological outcomes in antiretroviral therapy-naïve individuals initiating second-generation integrase inhibitors
Daniele Armenia, Greta Marchegiani, Daniele Spalletta, et al.
Plos One
|
September 28, 2019
A prospective randomized trial on abacavir/lamivudine plus darunavir/ritonavir or raltegravir in HIV-positive drug-naïve patients with CD4<200 cells/uL (the PRADAR study)
Cristina Mussini, Enrica Roncaglia, Vanni Borghi, et al.
The Journal of Antimicrobial Chemotherapy
|
May 15, 2026
'Leaving no stones unturned': up to 10 years results on the effectiveness, tolerability and metabolic safety of dolutegravir+lamivudine (DTG+3TC) as a switch regimen in the ODOACRE cohort
Arturo Ciccullo, Gianmaria Baldin, Adriana Cervo, et al.
Expert Review of Anti-Infective Therapy
|
October 15, 2020
Enhancing care for people living with HIV: current and future monitoring approaches
Franco Maggiolo, Alessandra Bandera, Stefano Bonora, et al.
The Lancet. HIV
|
February 28, 2024
Switching to dolutegravir plus rilpivirine versus maintaining current antiretroviral therapy regimen in virologically suppressed people with HIV-1 and the Lys103Asn (K103N) mutation: 48-week results from a randomised, open-label pilot clinical trial
Graeme Moyle, Lambert Assoumou, Nathalie de Castro, et al.
Immunity, Inflammation and Disease
|
February 25, 2023
Reduced probability of improving viro-immunological state in subjects with vertical transmission of HIV reaching adult age: A multicenter retrospective cohort study
Francesca Pennati, Stefano Calza, Antonio Di Biagio, et al.
Page
of 20